Zepbound beats Wegovy for weight loss in first head-to-head trial of blockbuster drugs

People taking Eli Lilly's obesity drug, Zepbound, mislaid astir 50% much value than those utilizing rival Novo Nordisk's Wegovy successful the archetypal head-to-head survey of the blockbuster medications.

Clinical proceedings participants who took tirzepatide, the cause sold arsenic Zepbound, mislaid an mean of 50 pounds (22.8 kilograms) implicit 72 weeks, portion those who took semaglutide, oregon Wegovy, mislaid astir 33 pounds (15 kilograms). That's according to the survey funded by Lilly, which was published Sunday successful the New England Journal of Medicine.

Both drugs are portion of a caller people of medications that enactment by mimicking hormones successful the gut and encephalon that modulate appetite and feelings of fullness. But tirzepatide targets 2 specified hormones, known arsenic GLP-1 and GIP, portion semaglutide targets GLP-1 alone, said Dr. Louis Aronne, manager of the Comprehensive Weight Control Center astatine Weill Cornell Medicine.

“Two drugs unneurotic tin nutrient amended value loss,” said Aronne, who led the survey and presented the findings Sunday astatine the European Congress connected Obesity successful Spain.

While tirzepatide won retired successful what Aronne said galore presumption arsenic “a resistance contention of efficacy,” some are important tools for treating obesity, which affects astir 40% of American adults.

“The constituent of these medications is to amended health,” helium said. “The bulk of radical won't request the astir effectual medication.”

The proceedings included 751 radical from crossed the U.S. who were overweight oregon had obesity and astatine slightest 1 different weight-related wellness problem, but not diabetes. Participants received play injections of the highest tolerated doses of Zepbound, either 10 milligrams oregon 15 milligrams, oregon Wegovy, 1.7 milligrams oregon 2.4 milligrams.

By the extremity of the trial, those who took Zepbound mislaid astir 20% of their assemblage value connected average, compared with a astir 14% nonaccomplishment for those who took Wegovy. The tirzepatide radical trimmed astir 7 inches (17.8 centimeters) from their waist circumference, compared to astir 5 inches (12.7 centimeters) with semaglutide. In addition, astir 32% of radical taking Zepbound mislaid astatine slightest a 4th of their assemblage weight, compared to astir 16% of those taking Wegovy, the survey found.

Weight nonaccomplishment was astir 6% little successful men than successful women successful some groups, the authors noted. As participants successful some groups mislaid much weight, they saw improvements successful wellness markers specified arsenic humor pressure, humor abdominous and humor sweetener levels.

More than three-quarters of patients taking some drugs reported astatine slightest 1 broadside effect, mostly mild to mean gastrointestinal issues specified arsenic nausea, constipation, diarrhea and vomiting. About 6% of participants taking Zepbound near the proceedings due to the fact that of adverse events, compared with 8% of those taking semaglutide.

The GLP-1 drugs person go progressively popular, with astatine slightest 1 successful 8 U.S. adults reporting their use, according to a 2024 survey by KFF, a autarkic wellness argumentation probe organization. Zepbound generated $4.9 cardinal successful planetary income past year. Wegovy brought successful astir $8.8 cardinal (58.2 billlion Danish kroner).

Access and affordability person constricted wider usage of the drugs. Tirzepatide and semaglutide were removed precocious from a database of cause shortages by the U.S. Food and Drug Administration. Both manufacturers precocious released programs that chopped costs to astir $500 per period oregon less, depending connected the dose.

Other factors tin impact access. This week, CVS Health said Wegovy volition go the preferred enactment connected its modular formulary, oregon database of covered drugs, arsenic of July 1. Zepbound volition beryllium excluded.

It's important to person a scope of drugs to dainty a illness arsenic wide arsenic obesity successful the U.S., said Dr. Angela Fitch, main aesculapian serviceman of knownwell, an obesity attraction company. Wegovy has been recovered to chopped the hazard of superior bosom problems by 20%, she noted. A cause whitethorn enactment good for 1 patient, but not for others.

“We're going to request to usage them each conscionable due to the fact that we person truthful galore patients who request treatment,” she added.

___

AP Health Writer Tom Murphy successful Indianapolis contributed to this report.

___

The Associated Press Health and Science Department receives enactment from the Howard Hughes Medical Institute’s Science and Educational Media Group and the Robert Wood Johnson Foundation. The AP is solely liable for each content.